OTIC Otonomy, Inc.

12.55
+0  (3%)
Previous Close 12.20
Open 12.30
Price To book 1.92
Market Cap 379.71M
Shares 30,256,000
Volume 88,564
Short Ratio 12.41
Av. Daily Volume 203,079

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2017.
OTO-104 AVERTS-1
Ménière's disease
Phase 2 trial to be initiated 2H 2017.
OTO-311
Tinnitus
Second Phase 3 trial initiated March 2016. Data from both Phase 3 trials due 2H 2017.
OTO-104 AVERTS-2
Ménière's disease
Phase 2 trial completed October 2016. End of Phase 2 meeting planned with FDA 1H 2017.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiation announced January 19, 2017.
OTO-104
Prevention of hearing loss in cancer patients undergoing chemotherapy
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Phase 3 trial met primary endpoint - January 5, 2017. sNDA filing to be submitted 1H 2017.
OTIPRIO
Acute otitis externa